Legal Representation
Attorney
Constance B. Stefanou
USPTO Deadlines
Next Deadline
14 days remaining
NOA E-Mailed - SOU Required
Due Date
February 25, 2026
Extension Available
Until August 25, 2026
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 27, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 27, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 27, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 27, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 25, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 31, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 31, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 25, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 9, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 9, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 9, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 9, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 9, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Sep 21, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 21, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 21, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 19, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 18, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 6, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 003
Cosmetics; ingredient complex composed of synthetic and collagen peptides sold as an integral component of cosmetic preparations;
Class 005
Synthetic and collagen peptides for use in the fields of medical diagnostics and biotechnology, namely, for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations for use in the fields of medical diagnostics and biotechnology, namely, topical drugs for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for pharmaceutical purposes for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides for the treatment of various conditions and diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; synthetic and collagen peptides sold as ingredient in pharmaceutical preparations for the treatment immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; pharmaceutical preparations containing synthetic and collagen peptides for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases; chemical preparations for sanitary use, namely, for coating medical devices, and for wound dressings; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; injectable pharmaceuticals for the treatment of immune mediated diseases, namely, dermal, eye, systemic, inflammatory, autoimmune, rheumatic, liver, and gastrointestinal conditions and diseases;
Classification
International Classes
003
005